Sotera Health (NASDAQ:SHC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sotera Health (NASDAQ:SHC) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $16.08.

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on shares of Sotera Health in a research note on Friday, December 6th. They set a “neutral” rating and a $14.00 price target on the stock.

Sotera Health Stock Performance

NASDAQ:SHC opened at $13.62 on Friday. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The firm has a market cap of $3.86 billion, a price-to-earnings ratio of 54.48 and a beta of 1.96. The firm’s fifty day moving average price is $14.05 and its 200 day moving average price is $14.32. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.18 EPS. On average, sell-side analysts expect that Sotera Health will post 0.61 EPS for the current year.

Institutional Trading of Sotera Health

Several large investors have recently modified their holdings of the business. William Blair Investment Management LLC lifted its stake in Sotera Health by 0.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after buying an additional 6,707 shares in the last quarter. Clearline Capital LP purchased a new stake in shares of Sotera Health in the second quarter valued at $1,707,000. Geode Capital Management LLC boosted its stake in shares of Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after acquiring an additional 447,186 shares during the last quarter. Maven Securities LTD purchased a new stake in Sotera Health during the 3rd quarter worth about $1,670,000. Finally, Darsana Capital Partners LP acquired a new position in Sotera Health in the 2nd quarter valued at about $29,074,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.